Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by TD Asset Management Inc

TD Asset Management Inc reduced its position in shares of Akero Therapeutics, Inc. (NASDAQ:AKROFree Report) by 25.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 94,202 shares of the company’s stock after selling 31,890 shares during the period. TD Asset Management Inc owned approximately 0.17% of Akero Therapeutics worth $2,200,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Alkeon Capital Management LLC grew its stake in shares of Akero Therapeutics by 8.7% in the 3rd quarter. Alkeon Capital Management LLC now owns 3,767,380 shares of the company’s stock worth $190,554,000 after purchasing an additional 300,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Akero Therapeutics by 12.1% during the third quarter. Vanguard Group Inc. now owns 3,012,182 shares of the company’s stock worth $152,356,000 after buying an additional 326,308 shares in the last quarter. FMR LLC grew its position in Akero Therapeutics by 6.3% in the third quarter. FMR LLC now owns 2,750,348 shares of the company’s stock worth $139,113,000 after buying an additional 162,820 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Akero Therapeutics by 16.9% in the third quarter. Northern Trust Corp now owns 538,023 shares of the company’s stock valued at $27,213,000 after buying an additional 77,594 shares in the last quarter. Finally, Eventide Asset Management LLC lifted its position in shares of Akero Therapeutics by 35.5% during the 3rd quarter. Eventide Asset Management LLC now owns 513,876 shares of the company’s stock valued at $25,992,000 after acquiring an additional 134,756 shares during the last quarter.

Analyst Upgrades and Downgrades

AKRO has been the topic of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a report on Monday, May 13th. Bank of America began coverage on Akero Therapeutics in a report on Monday, April 22nd. They set a “neutral” rating and a $30.00 price objective on the stock. Evercore ISI decreased their target price on shares of Akero Therapeutics from $50.00 to $38.00 and set an “outperform” rating for the company in a report on Wednesday, May 15th. UBS Group lifted their target price on shares of Akero Therapeutics from $39.00 to $42.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. Finally, Canaccord Genuity Group decreased their price objective on shares of Akero Therapeutics from $59.00 to $56.00 and set a “buy” rating for the company in a research note on Monday, May 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $41.13.

Read Our Latest Stock Analysis on AKRO

Akero Therapeutics Price Performance

NASDAQ AKRO opened at $23.02 on Friday. The company has a 50 day simple moving average of $20.78 and a 200-day simple moving average of $22.04. Akero Therapeutics, Inc. has a 52-week low of $11.25 and a 52-week high of $58.38. The firm has a market capitalization of $1.59 billion, a price-to-earnings ratio of -7.19 and a beta of -0.31. The company has a debt-to-equity ratio of 0.04, a current ratio of 30.12 and a quick ratio of 30.12.

Akero Therapeutics (NASDAQ:AKROGet Free Report) last released its earnings results on Friday, May 10th. The company reported ($0.90) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.90). Equities research analysts predict that Akero Therapeutics, Inc. will post -3.87 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Akero Therapeutics news, COO Jonathan Young sold 5,000 shares of the business’s stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $20.15, for a total value of $100,750.00. Following the transaction, the chief operating officer now owns 258,306 shares in the company, valued at $5,204,865.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last ninety days, insiders sold 15,000 shares of company stock worth $319,100. Corporate insiders own 7.94% of the company’s stock.

Akero Therapeutics Profile

(Free Report)

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.

Recommended Stories

Want to see what other hedge funds are holding AKRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akero Therapeutics, Inc. (NASDAQ:AKROFree Report).

Institutional Ownership by Quarter for Akero Therapeutics (NASDAQ:AKRO)

Receive News & Ratings for Akero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.